Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Modality: T cell-engaging bispecific antibody
Disease State: Previously untreated large B-cell lymphoma (LBCL), Relapsed or refractory mantle cell lymphoma (MCL)
Summary
Glofitamab is a bispecific antibody that binds to CD20 expressed on the surface of B cells and to the CD3 receptor expressed on the surface of T cells. Glofitamab causes T-cell activation and proliferation, secretion of cytokines, and the lysis of CD20-expressing B cells.1
Clinical Trials
Glofitamab
| NCT ID | Study Phase | Enrollment Status | Study Title | |
|---|---|---|---|---|
| NCT06047080 | Phase III | Active, not recruiting | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | View details |
| NCT04980222 | Phase II | Active, not recruiting | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | View details |
| NCT03075696 | Active, not recruiting | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | View details | |
| NCT06084936 | Phase III | Recruiting | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | View details |
Proposed Mechanism of Action
Glofitamab is a bispecific antibody that binds to CD20 expressed on the surface of B cells and to the CD3 receptor expressed on the surface of T cells. Glofitamab causes T-cell activation and proliferation, secretion of cytokines, and the lysis of CD20-expressing B cells.1
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT